Articles related to BIOMARKERS

Tumor genomes may evolve during treatment as resistant subclones emerge under therapeutic pressure, prompting increasing use of comprehensive genomic profiling and serial ctDNA testing to inform ongoing precision oncology decisions.

Prostate cancer screening continues to rely on individualized risk assessment, PSA monitoring, and shared decision-making, while advances in MRI imaging and biomarker testing may help refine biopsy decisions and reduce unnecessary invasive procedures.

Loss of the membrane-regulating protein NSF in dopamine D2 receptor-expressing neurons was associated with hyperactivity, impulsive behavior, and reduced striatal dopamine signaling in mice. The findings offer mechanistic insight into ADHD biology, although clinical relevance remains unproven.

A prospective multicenter study of 970 adults with suspected mild traumatic brain injury (TBI) found that a rapid point-of-care blood test measuring GFAP and UCH-L1 achieved 96.5% sensitivity and 96.5% negative predictive value for detecting CT-positive intracranial injury, supporting its potential role in reducing unnecessary head CT imaging.

An experimental cell therapy that couples a patient’s red blood cells with myelin protein fragments was well tolerated in a 10-patient Phase 1b study and was associated with increases in regulatory T-cells and reductions in neurofilament light chain, a biomarker linked to nerve injury.

Artificial intelligence tools are increasingly being integrated into prostate cancer imaging, pathology, prognostication, and treatment planning. Although several platforms have demonstrated promising accuracy and workflow benefits, broad clinical adoption will require prospective validation, regulatory oversight, and careful implementation.